These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 37507210)

  • 1. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
    Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R
    RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies for Spondyloarthritis: Implementation of precision medicine - Or "one size fits all" concept?
    Proft F; Duran TI; Ghoreschi K; Pleyer U; Siegmund B; Poddubnyy D
    Autoimmun Rev; 2024 Oct; 23(10):103638. PubMed ID: 39276959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging treatment options for spondyloarthritis.
    Torgutalp M; Poddubnyy D
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors.
    Chan J; Gladman D
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
    Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of axial spondyloarthritis: an update.
    Danve A; Deodhar A
    Nat Rev Rheumatol; 2022 Apr; 18(4):205-216. PubMed ID: 35273385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials.
    Kawka L; Chevet B; Arnaud L; Becker G; Carvajal Alegria G; Felten R
    Autoimmun Rev; 2024; 23(7-8):103590. PubMed ID: 39122202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
    Séauve M; Auréal M; Laplane S; Lega JC; Cabrera N; Coury F
    Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
    Braun J; Kiltz U; Baraliakos X
    Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in ankylosing spondylitis-status in 2021.
    Klavdianou K; Tsiami S; Baraliakos X
    Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi29-vi37. PubMed ID: 34951921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
    Gialouri CG; Pappa M; Evangelatos G; Nikiphorou E; Fragoulis GE
    Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
    Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
    Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RBM; Van den Bosch FE; Boteva B; Bremander A; Carron P; Ciurea A; van Gaalen FA; Géher P; Gensler L; Hermann J; de Hooge M; Husakova M; Kiltz U; López-Medina C; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compán V; Nissen MJ; Pimentel-Santos FM; Poddubnyy D; Proft F; Rudwaleit M; Telkman M; Zhao SS; Ziade N; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):19-34. PubMed ID: 36270658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Axial Spondyloathritis Treatment.
    Maguire S; Sengupta R; O'Shea F
    Rheum Dis Clin North Am; 2020 May; 46(2):357-365. PubMed ID: 32340707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
    Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
    J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.